Bright Futures Wealth Management LLC. Takes Position in Merck & Co., Inc. $MRK

Bright Futures Wealth Management LLC. purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 5,628 shares of the company’s stock, valued at approximately $472,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its stake in Merck & Co., Inc. by 9.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company’s stock worth $4,263,991,000 after purchasing an additional 4,636,183 shares during the period. DLD Asset Management LP acquired a new stake in shares of Merck & Co., Inc. during the second quarter worth $2,889,340,000. Norges Bank purchased a new position in Merck & Co., Inc. in the 2nd quarter valued at $2,858,570,000. Franklin Resources Inc. grew its position in Merck & Co., Inc. by 23.5% in the 2nd quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company’s stock valued at $2,139,901,000 after buying an additional 5,135,748 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in Merck & Co., Inc. by 2.3% during the 2nd quarter. Fisher Asset Management LLC now owns 25,013,697 shares of the company’s stock worth $1,980,084,000 after buying an additional 567,900 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

MRK has been the topic of several analyst reports. Bank of America lifted their target price on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a report on Monday, December 15th. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a report on Friday, February 13th. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday. Barclays assumed coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 price target on the stock. Finally, The Goldman Sachs Group increased their price objective on Merck & Co., Inc. from $92.00 to $120.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $125.88.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $123.45 on Monday. The firm has a market cap of $305.22 billion, a price-to-earnings ratio of 16.96, a price-to-earnings-growth ratio of 2.40 and a beta of 0.27. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The company’s 50-day moving average is $112.93 and its two-hundred day moving average is $97.49. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same quarter in the prior year, the company posted $1.72 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Research analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is 46.70%.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the transaction, the executive vice president owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. This trade represents a 63.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Caroline Litchfield sold 41,997 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total transaction of $5,023,261.17. Following the sale, the chief financial officer directly owned 90,192 shares of the company’s stock, valued at approximately $10,787,865.12. This trade represents a 31.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 320,176 shares of company stock valued at $38,281,735 in the last three months. 0.09% of the stock is owned by company insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.